drugset / Trial / NCT06613997
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
Phase 3
Not yet recruiting
100 enrolled
Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Institut de Recherche pour le Developpement · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.
Timeline
- Start
- 2025-01-15
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albendazole | Small molecule | 400 mg | — |